United Therapeutics (UTHR) Operating Expenses (2009 - 2026)

United Therapeutics has disclosed Operating Expenses across 18 years of filings, most recently posting $452.5 million for Q2 2026.

• In Q2 2026, Operating Expenses rose 4.24% year-over-year to $452.5 million; the TTM figure through Jun 2026 stood at $1.8 billion (up 7.55% YoY), while the FY2025 annual figure was $1.7 billion, up 12.65% from the prior year.
• Operating Expenses came in at $452.5 million for Q2 2026 at United Therapeutics, down from $455.7 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $455.7 million in Q1 2026 to a low of $173.9 million in Q1 2022.
• Average Operating Expenses over 5 years is $344.3 million, with a median of $366.4 million recorded in 2023.
• Year-over-year, Operating Expenses sank 60.82% in 2022 and soared 44.45% in 2024.
• Over 5 years, Operating Expenses stood at $315.9 million in 2022, then grew by 12.25% to $354.6 million in 2023, then rose by 6.66% to $378.2 million in 2024, then climbed by 14.62% to $433.5 million in 2025, then climbed by 4.38% to $452.5 million in 2026.
• Per Business Quant data, the three most recent Operating Expenses figures were $452.5 million in Q2 2026, $455.7 million in Q1 2026, and $433.5 million in Q4 2025.